Understanding the Market | FOSUN PHARMA rose nearly 4% during the session, with net profit attributable to the parent company increasing by 25.5% year-on-year in the first three quarters. The company continues to promote the launch of innovative products

FOSUN PHARMA rose nearly 4% during the session, and as of the time of writing, it was up 3.76%, trading at HKD 23.16, with a transaction volume of HKD 50.4121 million. In terms of news, recently, FOSUN PHARMA released its performance for the nine months ending September 30, 2025, reporting an operating income of RMB 29.393 billion, a year-on-year decrease of 4.91%; net profit attributable to shareholders of the listed company was RMB 2.523 billion, a year-on-year increase of 25.5%; basic earnings per share were RMB 0.95. The announcement stated that the total profit and net profit attributable to shareholders of the listed company for the first three quarters of 2025, as well as basic and diluted earnings per share, increased year-on-year, mainly due to the contribution from the sale of remaining equity in United Family Healthcare and other non-core assets. Yuanta Securities pointed out that in Q3 2025, FOSUN PHARMA continued to promote the launch of innovative products, with the innovative small molecule CDK4/6 inhibitor, Ruzhoning, newly approved for an indication in China in September, HLX14 (Dulizumab injection) approved for listing in the United States and the European Union in September, and FKC889 (Brezekoren injection) also submitted for listing in China, which was accepted by the National Medical Products Administration in September. The firm believes that as the company's innovative drug products are gradually launched, it will drive a rebound in revenue